Skip to main content

Table 3 Univariate Cox regression analysis of all-cause death in patients with atrial fibrillation

From: Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation

  HR represents Total population
n = 433
EHRA Type 1
n = 91
ERHA Type 2
n = 59
Patients without VHDs
n = 283
Male Versus female 2.182 (1.332–3.576), 0.002 1.761 (0.708–4.384), 0.224 1.999 (0.516–7.745), 0.316 3.086 (1.483–6.421), 0.003
Age Per 1-year increment 1.024 (1.004–1.045), 0.017 1.052 (1.007–1.100), 0.024 1.029 (0.982–1.078),0.229 1.018 (0.991–1.045), 0.189
BMI (kg/m2) Per 1 kg/m2 increment 0.908 (0.848–0.973), 0.006 0.812 (0.693–0.952), 0.010 0.899 (0.730–1.108),0.319 0.957 (0.878–1.043), 0.317
Systolic blood pressure Per 1 mmHg increment 0.989 (0.978–1.001), 0.073 0.987 (0.964–1.010), 0.274 0.993 (0.965–1.022), 0.653 0.990 (0.975–1.005),0.202
Heart rate Per 1 bpm increment 0.990 (0.982–0.998), 0.016 0.987 (0.970–1.004), 0.139 0.992 (0.969–1.016), 0.513 0.992 (0.982–1.002), 0.110
Duration of AF      
 Persistent Versus Paroxysmal 0.781 (0.365–1.670), 0.524 1.743 (0.181–16.767), 0.630 3.024 (0.424–21.541),0.269 0.650 (0.264–1.597), 0.347
 Permanent Versus Paroxysmal 2.128 (1.068–4.237), 0.032 3.409 (0.450–25.818), 0.235 1.348 (0.272–6.688),0.714 2.492 (1.061–5.851), 0.036
Smoking Yes versus no 1.844 (1.149–2.960), 0.011 1.136 (0.331–3.898), 0.840 1.655 (0.466–5.878), 0.436 2.439 (1.336–4.415), 0.004
Hypertension Yes versus no 0.729 (0.459–1.158), 0.181 0.994 (0.230–2.092), 0.516 0.995 (0.288–3.440),0.993 0.736 (0.407–1.331), 0.311
Diabetes Yes versus no 1.200 (0.754–1.910), 0.442 1.368 (0.550–3.402), 0.500 0.411 (0.106–1.591),0.198 1.447 (0.798–2.623), 0.224
Hypercholesterolemia Yes versus no 1.426 (0.348–5.851), 0.622 NA 1.584 (0.199–12.609),0.664 1.246 (0.169–9.181), 0.829
TIA or stroke Yes versus no 1.181 (0.621–2.244), 0.612 1.725 (0.502–5.937), 0.387 1.430 (0.179–11.388),0.736 1.072 (0.477–2.410), 0.866
CADs Yes versus no 1.485 (0.900–2.451), 0.122 0.044 (0.000–91.652), 0.424 0.419 (0.053–3.309),0.409 2.537 (1.392–4.622), 0.002
Heart failure Yes versus no 3.393 (1.967–5.853), < 0.001 2.422 (0.559–10.503), 0.237 NA 3.872 (2.059–7.283), < 0.001
CHA2DS2-VASc Score Per 1 score increment NA NA 1.000 (0.656–1.525),0.999 1.159 (0.986–1.363), 0.074
ALT Per 1 U/l increment 1.002 (1.001–1.004), < 0.001 1.001 (0.998–1.004), 0.506 0.917 (0.839–1.002), 0.056 1.003 (1.001–1.004), < 0.001
eGFR Per 1 ml/(min·1.73 m2) increment 0.982 (0.971–0.993), 0.001 0.990 (0.970–1.009), 0.292 0.993 (0.965–1.022), 0.634 0.974 (0.959–0.990), 0.001
Warfarin Yes versus no 1.065 (0.637–1.781), 0.811 0.680 (0.276–1.675),0.402 1.054 (0.297–3.736), 0.935 1.098 (0.464–2.600), 0.832
TiTR  ≥ 66% versus < 66% 0.551 (0.173–1.750), 0.312 0.533 (0.155–1.830), 0.317 NA NA
  1. HR indicates hazard ratio
  2. Data are presented as HR (95% confidential interval), P value
  3. CHA2DS2-VASc score was calculated by congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke or TIA (doubled), vascular disease, Age 65 to74 years, female Sex
  4. NA not available, VHD valvular heart diseases, BMI body mass index, TIA transient ischemic attack, CAD coronary artery disease, IQR interquartile range, GFR estimated Glomerular filtration rate, AF atrial fibrillation